Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Tislelizumab + nab-paclitaxel is a combination therapy consisting of tislelizumab, a humanized anti-PD-1 monoclonal antibody engineered to minimize binding to FcγR on macrophages, and nab-paclitaxel, a nanoparticulate formulation of paclitaxel bound to human serum albumin. This combination represents an immunotherapy plus chemotherapy approach that has demonstrated efficacy in multiple cancer types including esophageal squamous cell carcinoma, non-small cell lung cancer, bladder cancer, and triple-negative breast cancer.
- Brand names
- Abraxane (nab-paclitaxel)Tislelizumab (no widely used brand name; often referred to by generic name)
- Other names
- tislelizumab + nab-paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + nab-paclitaxel.